The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Incyte Corp’s stock clocked out at $95.41, down -0.72% from its previous closing price of $96.1. In other words, the price has decreased by -$0.72 from its previous closing price. On the day, 2.16 million shares were traded. INCY stock price reached its highest trading level at $96.0 during the session, while it also had its lowest trading level at $93.54.
Ratios:
To gain a deeper understanding of INCY’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.39 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.65. For the most recent quarter (mrq), Quick Ratio is recorded 3.13 and its Current Ratio is at 3.20. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On November 03, 2025, Guggenheim Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $125.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 10 ’25 when Mayes Patrick A sold 5,553 shares for $95.58 per share. The transaction valued at 530,756 led to the insider holds 60,266 shares of the business.
Mayes Patrick A sold 255 shares of INCY for $24,210 on Dec 11 ’25. The EVP & Chief Scientific Officer now owns 60,011 shares after completing the transaction at $94.94 per share. On Dec 11 ’25, another insider, PATRICK A MAYES, who serves as the Officer of the company, bought 255 shares for $94.94 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INCY now has a Market Capitalization of 18731149312 and an Enterprise Value of 15842595840. As of this moment, Incyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.01, and their Forward P/E ratio for the next fiscal year is 12.26. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.12. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.89 while its Price-to-Book (P/B) ratio in mrq is 4.02. Its current Enterprise Value per Revenue stands at 3.292 whereas that against EBITDA is 11.963.
Stock Price History:
The Beta on a monthly basis for INCY is 0.82, which has changed by 0.37679088 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, INCY has reached a high of $109.28, while it has fallen to a 52-week low of $53.56. The 50-Day Moving Average of the stock is -1.17%, while the 200-Day Moving Average is calculated to be 23.70%.
Shares Statistics:
It appears that INCY traded 2.19M shares on average per day over the past three months and 2197890 shares per day over the past ten days. A total of 196.13M shares are outstanding, with a floating share count of 194.23M. Insiders hold about 1.07% of the company’s shares, while institutions hold 103.66% stake in the company. Shares short for INCY as of 1764288000 were 9149380 with a Short Ratio of 4.18, compared to 1761868800 on 9517258. Therefore, it implies a Short% of Shares Outstanding of 9149380 and a Short% of Float of 6.569999999999999.
Earnings Estimates
A detailed examination of Incyte Corp (INCY) is currently in progress, with 16.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $1.61, with high estimates of $1.9 and low estimates of $1.33.
Analysts are recommending an EPS of between $7.16 and $6.53 for the fiscal current year, implying an average EPS of $6.83. EPS for the following year is $7.7, with 20.0 analysts recommending between $9.33 and $5.38.
Revenue Estimates
In. The current quarter, 18 analysts expect revenue to total $1.35B. It ranges from a high estimate of $1.43B to a low estimate of $1.3B. As of. The current estimate, Incyte Corp’s year-ago sales were $1.18BFor the next quarter, 18 analysts are estimating revenue of $1.25B. There is a high estimate of $1.36B for the next quarter, whereas the lowest estimate is $1.18B.
A total of 21 analysts have provided revenue estimates for INCY’s current fiscal year. The highest revenue estimate was $5.06B, while the lowest revenue estimate was $4.92B, resulting in an average revenue estimate of $4.98B. In the same quarter a year ago, actual revenue was $4.24BBased on 20 analysts’ estimates, the company’s revenue will be $5.52B in the next fiscal year. The high estimate is $5.82B and the low estimate is $5.13B.
